home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Drug Promise For Renal Disease

  December, 6 2006 9:19
your information resource in human molecular genetics
A drug that alters renal cell proliferation may prove a useful treatment for polycystic kidney disease, a mouse study suggests in a paper published online by Nature.

Oxana Ibraghimov-Beskrovnaya and colleagues found that (r)-roscovitine, a drug that interferes with cell proliferation, slows disease progression in two mouse models of autosomal dominant polycystic kidney disease (ADPKD). A single pulse treatment produced robust, long-lasting effects in mice, and was effective against cysts found in different parts of the kidney.

Human ADPKD is a late-onset genetic disorder without effective treatment. Fluid-filled cysts form in the kidney tubules, leading to renal failure. The researchers suspect that the cells making up the hair-like cilia that line the kidney tubules have abormal cell cycles. (r)-roscovitine alters this by inhibiting enzymes called cyclin-dependent kinases.


Oxana Ibraghimov-Beskrovnaya (Genzyme Corporation, Framingham, MA, USA)
E-mail: oxana.beskrovnaya@genzyme.com

Abstract available online.

(C) Nature press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2018 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.